EFFECTS OF DEPRENYL ON MONOAMINE-OXIDASE AND NEUROTRANSMITTERS IN THE BRAINS OF MPTP-TREATED AGING MICE

被引：9

作者：

GUPTA, M ^{[1
]}

WIENER, HL ^{[1
]}

机构：

[1] NATHAN S KLINE INST PSYCHIAT RES,ORANGEBURG,NY 10962

来源：

NEUROCHEMICAL RESEARCH | 1995年 / 20卷 / 04期

关键词：

DEPRENYL; AGING; MPTP; MAO-B; SEROTONIN; DOPAMINE TURNOVER;

D O I：

10.1007/BF00973091

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Deprenyl is a selective monoamine oxidase B (MAO-B) inhibitor and has been used in the treatment of Parkinson's disease. However, it is not known whether deprenyl effects are symptomatic or pharmacological. Aging mice were partially lesioned with MPTP. Control and MPTP-treated mice were given deprenyl in drinking water for 14 days. Brain tissue (including the striatum, olfactory tubercle and cerebral cortex) was assayed for MAO-B and neurotransmitter levels. The results show that deprenyl treatment, given alone or after MPTP, reduced MAO-B activity in all the three regions. No change was seen in dopamine (DA), 3,4-dihydroxyphenyl acetic acid (DO-PAC), and homovanillic acid (HVA) content in any of the three areas. Cortical norepinephrine (NE) levels were also unaltered. However, striatal serotonin (5-HT) levels were decreased while its metabolite, 5-HIAA levels were significantly increased in the olfactory tubercle in animals receiving deprenyl alone. These data suggest that deprenyl treatment reduces MAO-B activity in regions in addition to the striatum without affecting norepinephrine, dopamine (DA) and its metabolites.

引用

页码：385 / 389

页数：5

共 17 条

[1]

Langston J.W., Ballard P., Tetrud J.W., Irwin I., Chronic parkinsonism in humans due to a product of meperidineanalog synthesis, Science, 219, pp. 979-980, (1983)

[2]

Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J., A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by n-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Proc. Natl. Acad. Sci. USA, 80, pp. 4546-4550, (1983)

[3]

Gupta M., Felten D.L., Gash D.M., MPTP alters central catecholamine neurons in addition to the nigrostriatal system, Brain Res. Bull., 13, pp. 737-742, (1984)

[4]

Gupta M., Gupta B.K., Thomas R., Bruemmer V., Sladek J.R., Felten D.L., Aged mice are more sensitive to MPTP treatment than young adults, Neurosci. Lett., 70, pp. 326-331, (1986)

[5]

Chiba K., Trevor A.J., Castagnoli N., Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase, Biochem. Biophys. Res. Commun., 120, pp. 574-578, (1984)

[6]

Cohen G., Pasik P., Cohen B., Leist A., Mytilineou C., Yahr M.D., Pargyline and deprenyl prevent the toxicity of MPTP in monkeys, Eur. J. Pharmacol., 106, pp. 209-210, (1985)

[7]

Shoulson I., Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP), Acta Neurol. Scand., 126, pp. 171-175, (1989)

[8]

Effect of deprenyl on the progression of disabilitu in early Parkinson's Disease, N. Engl. J. Med., 321, 20, pp. 1364-1371, (1989)

[9]

Ingram D.K., Wiener H.L., Chachich M.E., Long J.M., Hengemihle J., Gupta M., Chronic treatment of aged mice with L-deprenyl produces marked striatal MAO-B inhibition but no beneficial effects on survival, motor performance, or nigral lipofuscin accumulation, Neurobiol. Aging, 14, pp. 431-440, (1993)

[10]

Wiener H.L., Hashim A., Lajtha A., Sershen H., Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice, J. Neurosci. Res., 23, pp. 326-329, (1989)

← 1 2 →